semaglutide nash results Effect of on fatty liver disease biomarkers in patients with diabetes and obesity FDA Approves First NASH Drug

The market is projected to grow from USD 56.62 billion in 2025 to USD 322.85 billion by 2034, exhibiting a CAGR of 21.3% during 20252034

Long-term use is generally considered safe when monitored by a healthcare provider

In metabolically robust individuals with preserved endocrine function, moderate proportional reductions in FFM may represent an expected and physiologically tolerable component of weight normalization

Wegovy, made by the same manufacturer, is the only semaglutide approved for weight management in young people aged 12-18, and only in addition to a reduced-calorie diet and increased physical activity

The dye temporarily tints your skin slightly yellow and colors your urine bright orange for several hours, but these effects are harmless and fade quickly

This consistency is what allows the medication to reshape your eating patterns and help you sustain a calorie deficit without constant hunger or cravings